TNBC, characterized by the absence of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2) expression, represents approximately 10–15% of all invasive breast cancers worldwide, with variations by region and population. The gene discussed is ERBB2; the disease is invasive breast carcinoma.